Loading clinical trials...

The Impact of Vitamin D on Disease Activity in Crohn's Disease | Clinical Trials | Clareo Health

TERMINATEDNA

The Impact of Vitamin D on Disease Activity in Crohn's Disease

NCT01864616•University of Saskatchewan

Summary

The purpose for this study is to determine the effect of vitamin D supplementation on disease activity in Crohn's disease patients in Canada and Saudi Arabia

Detailed Description

Hypothesis 1: Patients who are suffering from Crohn's disease are at risk of vitamin D deficiency. To determine vitamin D status and disease activity in Crohn's disease cases in Canada and Saudi Arabia. Hypothesis 2: Providing vitamin D in doses higher than RDA (Recommended Dietary Allowance) reduces disease activity in Crohn's disease cases. To evaluate the impact vitamin D in doses higher than RDA (Recommended Dietary Allowance) on disease activity in Crohn's disease patients.

Eligibility

Age

16 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•newly diagnosis with an active Crohn's disease,
•age above of 16 years

Exclusion Criteria

•remission or the duration of disease is more than 2 years,
•pregnancy,
•liver or kidney failure,
•inability to take oral supplements or medicine

Locations (2)

IBD clinic; Royal University Hospital

Saskatoon, Saskatchewan, Canada

Internal Medicine Department; King Abdulaziz University Hospital

Jeddah, Saudi Arabia

Key Dates

Start Date

July 1, 2013

Primary Completion Date

March 1, 2015

Completion Date

March 1, 2015

Last Updated

May 14, 2018

Enrollment

ACTUAL participants

Conditions

Crohn Disease

Interventions

Vitamin D3

DIETARY_SUPPLEMENT

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

NCT07245394

Inflammatory Bowel Disease (IBD)Crohn Disease (CD)+2 more

View study

RECRUITING

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

NCT07089420

IBD (Inflammatory Bowel Disease)IBS - Irritable Bowel Syndrome+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 14, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Impact of Vitamin D on Disease Activity in Crohn's Disease

Inclusion Criteria

Exclusion Criteria

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

Immunological Characteristics of Preclinical IBD

Impact of Exclusion Diet in Addition to Anti-TNF Therapy in Crohn's Disease and Ulcerative Colitis: a Prospective, Randomized, Double-arm, Open-label Study

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

Robotic Inflammatory Bowel Disease Development, Learning and Efficacy Study